- call +1-201-465-4211
- email sales@mrinsights.biz
Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment. According to Alzheimer’s Association, in 2016, an estimated 5.4 million Americans of all ages have Alzheimer's disease. One in nine people aged 65 and above has Alzheimer's disease. By 2050, the number of people aged 65 and above affected with Alzheimer's disease is expected to nearly triple, from 5.2 million to an expected 13.8 million, excluding the development of medical advances to avert or cure the disease. The mortality rates due to Alzheimer’s disease are quite high. Between 2000 and 2013, deaths due to heart disease, stroke and prostate cancer decreased 14%, 23% and 11%, respectively, while deaths from AD increased 71% in the U.S. Similarly, According to Alzheimer’s disease International in 2015, there are an estimated 46.8 million people worldwide living with dementia and is further expected to grow in future. Thus, there is an increasing in the demand for Alzheimer’s therapeutics and diagnostics worldwide.
Population aging across the globe is a major factor driving the market for Alzheimer’s therapeutics and diagnostics. Rising life expectancy is contributing to quick increases in number of aged population, and is associated with increased prevalence of chronic diseases like dementia. Therapies for AD offer temporary and uncertain improvements in the well-being of individuals, and none of the approved drugs can modify the course of the disease advancement. Thus, the magnitude of the affected population and lack of suitable and effective treatment offers an incredible opportunity for drug manufacturers. However, identification of the primary reasons and mechanisms involved in AD are is limited. Drug manufacturers have been unable to validate significant clinical benefits of treatment for a numerous of new compounds due to strict regulations. One of the significant trend observed in this market is collaboration of the existing players. Precisely, diagnostic technology companies are carefully trying to bring about effective biomarker technologies to support and improve the drug development process for potential drug candidates which is further expected to propel the demand.
Scope of the Report:
This report focuses on the Alzheimer's Disease Therapeutics and Diagnostics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Alzheimer's Disease Therapeutics and Diagnostics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Namenda
Aricept
Exelon
Solanezumab
Gantenerumab
Verubecestat
Pfizer
Eisai
Actavis
Lundbeck
Daiichi Sankyo
Novartis
TauRx
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Biomarkers
Cholinesterase inhibitors
NMDA receptor antagonists
Brain imaging
Blood tests
Market Segment by Applications, can be divided into
Drugs Market
Diagnostics Market
There are 15 Chapters to deeply display the global Alzheimer's Disease Therapeutics and Diagnostics market.
Chapter 1, to describe Alzheimer's Disease Therapeutics and Diagnostics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Alzheimer's Disease Therapeutics and Diagnostics, with sales, revenue, and price of Alzheimer's Disease Therapeutics and Diagnostics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Alzheimer's Disease Therapeutics and Diagnostics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Alzheimer's Disease Therapeutics and Diagnostics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Alzheimer's Disease Therapeutics and Diagnostics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Alzheimer's Disease Therapeutics and Diagnostics Introduction
1.2 Market Analysis by Type
1.2.1 Biomarkers
1.2.2 Cholinesterase inhibitors
1.2.3 NMDA receptor antagonists
1.2.4 Brain imaging
1.2.5 Blood tests
1.3 Market Analysis by Applications
1.3.1 Drugs Market
1.3.2 Diagnostics Market
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Namenda
2.1.1 Business Overview
2.1.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Namenda Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Aricept
2.2.1 Business Overview
2.2.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Aricept Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Exelon
2.3.1 Business Overview
2.3.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Exelon Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Solanezumab
2.4.1 Business Overview
2.4.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Solanezumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Gantenerumab
2.5.1 Business Overview
2.5.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Gantenerumab Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Verubecestat
2.6.1 Business Overview
2.6.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Verubecestat Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Pfizer
2.7.1 Business Overview
2.7.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Pfizer Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Eisai
2.8.1 Business Overview
2.8.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Eisai Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Actavis
2.9.1 Business Overview
2.9.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Actavis Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Lundbeck
2.10.1 Business Overview
2.10.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Lundbeck Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Daiichi Sankyo
2.11.1 Business Overview
2.11.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Daiichi Sankyo Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 Novartis
2.12.1 Business Overview
2.12.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Novartis Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 TauRx
2.13.1 Business Overview
2.13.2 Alzheimer's Disease Therapeutics and Diagnostics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 TauRx Alzheimer's Disease Therapeutics and Diagnostics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Alzheimer's Disease Therapeutics and Diagnostics Manufacturer Market Share in 2017
3.3.2 Top 6 Alzheimer's Disease Therapeutics and Diagnostics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Alzheimer's Disease Therapeutics and Diagnostics Market Analysis by Regions
4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Regions
4.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Regions (2013-2018)
4.2 North America Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
4.3 Europe Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
4.5 South America Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
5 North America Alzheimer's Disease Therapeutics and Diagnostics by Countries
5.1 North America Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Countries
5.1.1 North America Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Countries (2013-2018)
5.2 United States Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
5.3 Canada Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
5.4 Mexico Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
6 Europe Alzheimer's Disease Therapeutics and Diagnostics by Countries
6.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Countries
6.1.1 Europe Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
6.3 UK Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
6.4 France Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
6.5 Russia Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
6.6 Italy Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics by Countries
7.1 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Countries (2013-2018)
7.2 China Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
7.3 Japan Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
7.4 Korea Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
7.5 India Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
8 South America Alzheimer's Disease Therapeutics and Diagnostics by Countries
8.1 South America Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Countries
8.1.1 South America Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
8.3 Argentina Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
8.4 Colombia Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics by Countries
9.1 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
9.3 UAE Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
9.4 Egypt Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
9.5 Nigeria Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
9.6 South Africa Alzheimer's Disease Therapeutics and Diagnostics Sales and Growth Rate (2013-2018)
10 Global Alzheimer's Disease Therapeutics and Diagnostics Market Segment by Type
10.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales and Market Share by Type (2013-2018)
10.1.2 Global Alzheimer's Disease Therapeutics and Diagnostics Revenue and Market Share by Type (2013-2018)
10.2 Biomarkers Sales Growth and Price
10.2.1 Global Biomarkers Sales Growth (2013-2018)
10.2.2 Global Biomarkers Price (2013-2018)
10.3 Cholinesterase inhibitors Sales Growth and Price
10.3.1 Global Cholinesterase inhibitors Sales Growth (2013-2018)
10.3.2 Global Cholinesterase inhibitors Price (2013-2018)
10.4 NMDA receptor antagonists Sales Growth and Price
10.4.1 Global NMDA receptor antagonists Sales Growth (2013-2018)
10.4.2 Global NMDA receptor antagonists Price (2013-2018)
10.5 Brain imaging Sales Growth and Price
10.5.1 Global Brain imaging Sales Growth (2013-2018)
10.5.2 Global Brain imaging Price (2013-2018)
10.6 Blood tests Sales Growth and Price
10.6.1 Global Blood tests Sales Growth (2013-2018)
10.6.2 Global Blood tests Price (2013-2018)
11 Global Alzheimer's Disease Therapeutics and Diagnostics Market Segment by Application
11.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Market Share by Application (2013-2018)
11.2 Drugs Market Sales Growth (2013-2018)
11.3 Diagnostics Market Sales Growth (2013-2018)
12 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast (2018-2023)
12.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales, Revenue and Growth Rate (2018-2023)
12.2 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Regions (2018-2023)
12.2.1 North America Alzheimer's Disease Therapeutics and Diagnostics Market Forecast (2018-2023)
12.2.2 Europe Alzheimer's Disease Therapeutics and Diagnostics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Alzheimer's Disease Therapeutics and Diagnostics Market Forecast (2018-2023)
12.2.4 South America Alzheimer's Disease Therapeutics and Diagnostics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Alzheimer's Disease Therapeutics and Diagnostics Market Forecast (2018-2023)
12.3 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Type (2018-2023)
12.3.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Type (2018-2023)
12.3.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share Forecast by Type (2018-2023)
12.4 Alzheimer's Disease Therapeutics and Diagnostics Market Forecast by Application (2018-2023)
12.4.1 Global Alzheimer's Disease Therapeutics and Diagnostics Sales Forecast by Application (2018-2023)
12.4.2 Global Alzheimer's Disease Therapeutics and Diagnostics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Alzheimer's Disease Therapeutics and Diagnostics Picture
Table Product Specifications of Alzheimer's Disease Therapeutics and Diagnostics
Figure Global Sales Market
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
